Introduction:
Kidney cancer is a relatively rare but deadly disease that is among the top ten causes of cancer-related deaths in men in the USA (1). Most kidney tumors are classified as renal cell carcinomas (RCC) and are highly therapy-resistant (2) (3) (4) . RCC is actually a histologically heterogeneous group of several distinct tumor subtypes that originate from the epithelial cells of the renal tubule. Each subtype, including clear cell (ccRCC, 70%), papillary (pRCC, 10-15%), chromophobe (5%), and collecting duct (<1%), is associated with unique morphological and genetic characteristics (3) .
RCC characteristically exhibits molecular and biochemical features associated with chronic responses to low oxygen (hypoxia) (4) . Adaptation to hypoxia is mediated by an O 2 -sensitive transcription factor known as hypoxia-inducible factor (HIF) (4) , and accumulated genetic, clinical, and experimental evidence suggests that constitutive (i.e. O 2 -independent) activation of HIF plays a causal role in the development and progression of RCC (4, 5) . In normoxic conditions, the α-subunit of HIF (HIF-α) is rapidly hydroxylated at specific proline residues within the oxygen-dependent degradation domain (ODD) by prolyl-4-hydroxylase domain-containing protein 2 (PHD2) (4) . Hydroxylation of HIF-α creates a binding interface for the von Hippel-Lindau tumor suppressor protein (VHL) which serves as the substrate recognition component of an E3 ubiquitin ligase complex that promotes the polyubiquitylation and subsequent proteasomal degradation of HIF-α (4). Conversely, reduced O 2 in hypoxic conditions prevents the hydroxylation/degradation of HIF-α. Stabilized HIF-α dimerizes with its β-subunit (HIF-β) and activates various target genes that collectively govern a wide array of processes relevant to cancer development and progression, most notably angiogenesis and metabolism (6) . endothelial cells (e.g. sunitinib, sorafenib, bevacizumab, etc.) are now routinely used for ccRCC patients, and have succeeded in increasing progression-free survival and quality of life.
However, these agents typically fail to achieve durable remission in most cases (7) , and little is known as to their utility for non-ccRCC subtypes as these patients were excluded from clinical trials (8) .
Another anti-angiogenesis therapeutic strategy is to target HIF directly, and several points of regulation have been exploited to develop novel HIF-inhibiting agents. These drugs include 1) mTOR inhibitors (rapamycin, temsirolimus, and everolimus) that interfere with the translation of HIF-α subunit transcripts; 2) histone deacetylase (HDAC) inhibitors, heat shock protein 90 (HSP90) inhibitors, and nonsteroidal anti-inflammatory drugs (NSAIDs) that enhance HIF-α subunit protein degradation; 3) anthracyclines (doxorubicin, daunorubicin) and DNA intercalating agents (echinomycin) that interfere with the binding of HIF to DNA; and 4) dimerization inhibitors that block the binding of HIF-α subunits with HIF-β (6, 9-12). All of these agents are in various stages of preclinical development, clinical trials, or clinical use.
Ionophores are lipophilic molecules that render membranes permeable to specific cations and are classified as mobile-carriers and channel-formers. These drugs are potent antibiotics and are used in veterinary medicine and as feed additives for agriculture (13, 14) . Mobile-carrier ionophores are known to exhibit broad-spectrum anticancer abilities and are capable of overcoming drug resistance, improving chemo-and radio-sensitization, and inhibiting oncogenic signaling (13, 15, 16) . Accumulated research has now demonstrated that ionophores are not simply nonspecific cytotoxic chemicals, but are also capable of working at multiple levels to selectively disrupt cancer cell growth and survival (17) . In contrast to the mobile-carriers, use of channel-formers as antitumor agents has not been widely evaluated. Gramicidin A (GA) is a prototypical channel-forming ionophore that forms a 4Å pore that can accommodate water, protons, and monovalent cations. Channel formation results in Na + influx, K + efflux, osmotic swelling, and cell lysis in biological systems (18, 19) and confers GA with potent antibiotic activity against Gram-positive bacteria, fungi, and protozoa (20, 21) . We have previously demonstrated that GA is toxic to RCC cells and induces metabolic dysfunction and cellular energy depletion (22) . In this study, we investigated whether treatment with GA specifically affects HIF in RCC cells. We found that GA destabilizes HIF-1α and HIF-2α in both normoxia and hypoxia leading to reduced HIF transcriptional activity and loss of target gene expression. We determined that GA accelerates the O 2 -dependent degradation of HIF-α subunits via upregulation of the VHL tumor suppressor protein. Furthermore, we show that in vivo administration of GA reduces the growth and angiogenesis of VHL-expressing RCC cell line tumor xenografts without significant toxicity in mice. To our knowledge, this is the first time that an ionophore has been reported to 1) specifically inhibit HIF-dependent hypoxia responses, and 2) specifically upregulate a tumor suppressor (VHL). Our results reveal an additional "targeted" role for GA as a potent inhibitor of HIF and suggest its utility as an antiangiogenic therapeutic agent for RCC tumors that express wild-type VHL. 
Materials and Methods

Cell culture
Reagents
The following chemicals were purchased from Sigma-Aldrich (St. Louis, MO); gramicidin A, monensin, valinomycin, calcimycin (A23187), MG132, and cobalt chloride.
Antibodies
We purchased primary antibodies specific for HIF-1α (BD Biosciences, San Jose, CA), 
Immunoblot Analysis
Cell lysates were prepared in a buffer containing 95 mM NaCl, 25 mM Tris pH 7.4, 0. Triton X-100, 1% IGEPAL (octylphenoxypolyethoxyethanol), 1mM β-glycerol phosphate, 1mM Na 3 VO 4 , 2.5mM Na 4 P 2 O 7 , 50mM NaF, and 12mM deoxycholate. Lysates were sonicated, centrifuged, and the protein concentrations of the supernatants were determined using the DC protein assay (Bio-Rad, Hercules, CA). Equal amounts of protein were then resolved by SDS-PAGE and transferred to nitrocellulose. The membranes were blocked in 5% non-fat milk in tris-buffered saline with 0.1% Tween 20 (TBS-T) and then incubated overnight at 4°C with primary antibodies diluted in 5% bovine serum albumin (BSA)/TBS-T. The following day, the membranes were washed and incubated with HRP-conjugated secondary antibodies diluted in 5% non-fat milk/TBS-T at room temperature for 1hr. The protein bands were visualized using Amersham ECL Prime (GE Healthcare, Piscataway, NJ). Images were acquired using Photoshop (Adobe Systems Inc., San Jose, CA) and relative quantification was performed using ImageJ (NIH, Bethesda, MD). Samples were assayed in a 384 well format in triplicate using a 7900HT Fast Real-Time PCR system (Applied Biosystems, Foster City, CA). Variation in cDNA loading was normalized to GAPDH expression, which remained constant at the 24hr incubation periods used, and relative expression was determined using the ΔΔCt method of relative quantification (RQ). Graphs represent the average RQ value with error bars (standard error of the RQ value) from one representative of three independent experiments. Graphs were generated using the GraphPad Prism Software (GraphPad Software, La Jolla, CA).
Luciferase Activity Assay
HEK293T cells were cotransfected with 100ng phRL-renilla and 2μg of pGL2-HREluciferase or 1μg of pcDNA3-ODD-luciferase using Lipofectamine 2000 and incubated for 24hr before drug treatment. Following drug treatment, the Dual-Luciferase Reporter Assay (Promega Corporation, Madison, WI) was performed according to the manufacturer's instructions. Briefly, lysates were prepared using the provided buffer and then diluted 1:10, then 2μL of diluted sample lysate was added in triplicate to a white-walled 96-well plate, mixed with 100μL of firefly luciferase assay substrate, and luminescence was immediately recorded using a VictorX4 plate reader (Perkin-Elmer, Waltham, MA). Then 100μL of renilla luciferase substrate was added to each well and luminescence was immediately recorded using the plate reader. Values were corrected for background luminescence using the reading from the media only, and the corrected values were first normalized to renilla luciferase (internal control) and then to the Fluorescence signals from Caki-1 xenografts were acquired at the end of the study using the Kodak In Vivo Multispectral FX PRO imaging system (Carestream, Woodbridge, CT) using the following settings: Ex. 550 nm, Em. 600 nm, no binning, f/stop 2.8, focal plane 13.1 mm, fieldof-view 119.1 mm.
Immunohistochemistry
Formalin fixed paraffin embedded (FFPE) samples of vehicle and GA treated tumors were prepared using routine procedures. 5μM sections were floated onto charged slides and dried for one hour at 65°C. Following deparaffinization in xylene and graded alcohols, tissues underwent 
heat-induced epitope retrieval using the Decloaking Chamber and Reveal Decloaking Buffer 
Statistics
qRT-PCR results were analyzed using one-way ANOVA followed by Dunnett's Multiple
Comparison Test. All other analyses were performed using two-tailed unpaired Student's T-test. 
Results:
GA reduces HIF-1α and HIF-2α protein expression:
Because constitutive activation HIF is central to RCC pathogenesis, we investigated whether GA affects the expression of HIF in RCC cells. Using Caki-1, SN12C, and ACHN cell lines, we found that treatment with GA for 24hr provoked a dose-dependent decrease in the expression of both HIF-1α and HIF-2α protein in these cell lines (Fig. 1A, left) . Since HIF-α subunits are stabilized by hypoxia (1%O 2 ), we next assessed whether GA reduces HIF-α expression in hypoxia. Exposure to 1%O 2 dramatically increased HIF-1α and HIF-2α as expected, but treatment with GA prevented this increase in a dose-dependent manner (Fig. 1A, right). Strikingly, 1μM GA was sufficient to reduce the hypoxic expression of both isoforms below even their normoxic level (Fig. 1A, lane 8) with the exception of HIF-1α in ACHN cells.
Concomitant analysis of HIF mRNA expression revealed that GA significantly altered transcript expression for only HIF-2α in SN12C cells (P = 0.01 by one-way ANOVA) (Fig. 1B) suggesting that GA primarily affects only HIF protein levels. Finally, we assessed whether mobile-carrier ionophores also reduce hypoxic HIF protein expression. We compared equal doses (0.5μM) of GA with monensin (MON, Na and HIF-2α at 72hr, VAL moderately reduced both proteins from 24-72hr, and CAL had no effect on either protein (Fig. 1C) . Only GA elicited a profound decrease in both isoforms that persisted from 24-72hr (Fig. 1C) . These data reveal that only GA is a potent inhibitor of HIF-1α and HIF-2α protein expression. Next we analyzed the effect of GA upon the transcriptional activity of HIF. We utilized HEK293T cells transfected with a HIF-responsive luciferase reporter plasmid that contains three hypoxia-response elements (HRE) from the PGK1 (phosphoglycerate kinase 1) gene upstream of firefly luciferase (25) . HIF-dependent luciferase activity was significantly stimulated by hypoxia, but treatment with GA diminished this activity to nearly zero ( Fig. 2A) . Next we measured the expression of various HIF targets in RCC cells. We found that hypoxic expression of CA-IX (carbonic anhydrase 9), GLUT-1 (glucose transporter 1), and GAPDH (glyceraldehyde 3-phosphate dehydrogenase) were all decreased by GA in a dose-dependent manner in SN12C cells (Fig. 2B left) . Similar results were obtained using Caki-1 and ACHN cells (with the exception of GAPDH in Caki-1 cells) (Fig 2B, right) . Collectively, these results demonstrate that GA attenuates hypoxia responses by preventing the transcriptional activation of HIFresponsive genes.
GA reduces HIF transcriptional activity and target gene expression:
on
GA destabilizes HIF through proline hydroxylation:
O 2 -dependent downregulation of HIF-α depends upon the proteasome to degrade ubiquitylated HIF. In order to elucidate whether GA employs this mechanism, we first measured HIF expression in HEK293T cells treated with increasing doses of GA in the absence or presence of the well-known proteasomal inhibitor MG-132 (10μM) (29) . Treatment with GA failed to reduce HIF-1α and HIF-2α protein expression in cells treated with MG-132 (Fig. 3A, left) indicating that GA destabilizes HIF by enhancing its degradation by the proteasome. This regulatory mechanism also requires the hydroxylation of conserved proline residues located within the ODD of HIF by PHD enzymes (30) . Inhibition of PHD activity using the hypoxia destabilization of these proteins by GA (Fig. 3A, right) . Similar results were also observed using CoCl 2 -treated Caki-1, SN12C, and ACHN cells (not shown). We then examined whether the ODD of HIF is involved in the GA-mediated inhibition of HIF activity. Using HEK293T cells transfected with a luciferase reporter plasmid that contains the ODD of HIF-1α fused in frame to firefly luciferase (26) we determined that treatment with GA significantly reduced ODDluciferase activity (P < 0.05 by T-test, Fig. 3B ). In a related experiment, we transfected HEK293T cells with either HA-tagged wild-type HIF-1α (HA-HIF-1α) (27) or ODD-mutant HIF-1α (HA-HIF1α-P402A/P564A) (28) . Treatment of these cells revealed that wild-type HIF-1α but not ODD-mutant HIF-1α was reduced by GA (Fig 3C) . Altogether, these results demonstrate that GA employs the O 2 -dependent regulatory mechanism to destabilize HIF protein via PHD-dependent hydroxylation of its ODD.
GA upregulates VHL protein expression:
Mutational inactivation of VHL occurs extensively in sporadic ccRCC (up to 80%), and a remaining proportion of tumors (<10%) silence the VHL gene through DNA methylation (31, 32) . Loss of VHL cripples the ability of the cell to degrade HIF in normoxia yielding chronic activation of the HIF transcriptional program (33) . In our aforementioned experiments we used VHL-expressing RCC cells to establish that GA destabilizes HIF through proline hydroxylation and proteasomal degradation. In order to ascertain whether VHL is involved in GA-mediated degradation of HIF we used the naturally VHL-deficient ccRCC cell line UMRC6 and found that GA failed to reduce HIF-1α or HIF-2α expression (Fig. 4A, left) . In contrast, treatment of VHLreconstituted UMRC6+VHL cells did yield a reduction in HIF-2α protein expression (Fig. 4A right). HIF-1α expression was undetectable in this cell line. These data demonstrate that VHL is essential for GA-mediated destabilization of HIF.
Although hypoxia reduces proline hydroxylation of HIF, it does not completely abolish it (34) . Since GA treatment reduced HIF expression even in hypoxic conditions (Fig. 1) and utilizes the O 2 -dependent degradation mechanism (Fig. 3) , we speculated that GA enhances a component of this pathway to accelerate HIF destabilization. We investigated this possibility and observed that treatment with GA dramatically increased the expression of VHL protein in a dose-dependent manner in HEK293T cells as well as Caki-1, SN12C, and ACHN RCC cells (Fig. 4B ). This increase was not reflected at the mRNA level as transcript expression was significantly elevated in only SN12C cells (P < 0.001 by one-way ANOVA) (Fig. 4C ). These results demonstrate that GA inhibits HIF by enhancing VHL expression.
GA inhibits the growth and angiogenesis of VHL-expressing RCC tumor xenografts:
Tumor growth and development beyond a microscopic mass depends on the recruitment of new blood vessels (35) . Our in vitro data suggested that GA may reduce tumor growth in vivo by disrupting tumor angiogenesis. We previously found that GA reduced the in vivo growth SN12C tumor xenografts in mice (22) . In order to evaluate the anti-angiogenic efficacy of GA, we performed a similar experiment in which we engrafted human Caki-1 RCC cells that express the red fluorescent protein td-Tomato and can be visualized in vivo. Once the average tumor volume reached ~85mm 3 , the mice were randomized into two groups (each n = 8) and administered 50μL of either vehicle solution or GA (0.22mg/kg) by intratumoral injection thrice weekly for 26 days. As shown in Fig. 5A and B, the control tumors were noticeably larger than the GA-treated tumors. We found that the average mass of the GA-treated tumors was 52% less than that of the control tumors ( Fig. 5C , P = 0.017 by T-test). Analysis of tumor growth revealed that the tumors of the GA group essentially failed to grow once treatment with GA was initiated (Fig. 5D) . The difference in mean tumor volume achieved significance at day 5 and continued throughout the duration of the study (P < 0.05). Significantly, the increased dose, frequency, and duration of GA treatment did not elicit significant toxicity as no changes in average body mass (Fig. 5E ) or activity levels were observed in the mice. Taken together, these data demonstrate that GA inhibits the growth of VHL-expressing RCC tumors.
In order to confirm that reduced tumor growth was due to a blockade of tumor angiogenesis, we histologically examined the tumor tissue. GA-treated tumors recapitulated our in vitro findings as we observed an overall increase in VHL immunostaining (Fig. 6A ) and a 57% reduction in the average number of CD31 positive microvessels in the GA-treated tumors (Veh = 7.13±0.18 vs. GA = 3.04±0.54, P = 0.0004) (Fig. 6A, B) . In agreement with these data, immunoblot analysis revealed that HIF-2α and GAPDH protein expression was also substantially reduced in the GA-treated tumors (Fig. 6C) . HIF-1α was not detectable by immunoblot but this result was not surprising as it has been reported that RCC growth in vivo is driven by HIF-2α but repressed by HIF-1α (5). Taken together, these results are consistent with our in vitro data and indicate that GA inhibits tumor growth through the suppression of HIF-dependent angiogenesis. 
Discussion:
Here we report for the first time that GA is a novel inhibitor of tumor angiogenesis. We have demonstrated that treatment with GA enhances VHL expression which destabilizes HIF-1α and HIF-2α protein to suppress the transcription of various HIF targets. Loss of the HIF transcriptional program leads to reduced tumor angiogenesis which curtails tumor growth in vivo. These novel findings suggest that GA has therapeutic potential as an angiogenesis inhibitor for VHL-positive RCCs and possibly for other cancers that express VHL.
GA-mediated destabilization of HIF-α subunits required both proline hydroxylation and VHL expression indicating that GA utilized the O 2 -dependent degradation mechanism to target HIF. Strikingly, GA reduced HIF expression even in hypoxic conditions. Although hypoxia (1%O 2 ) limits PHD-mediated hydroxylation by depleting molecular oxygen, it does not completely abolish it (34) . We determined that GA increases the expression of VHL protein to accelerate O 2 -dependent degradation of HIF. Because upregulation of VHL was sufficient to compensate for the inhibitory effects of hypoxia, we suggest that VHL levels are another important limiting factor in the regulation of HIF in hypoxic conditions. However, whether GA also increases PHD expression and/or activity is an additional possibility that remains for further investigation.
To our knowledge, this is the first time that an ionophore has been shown to specifically upregulate a tumor suppressor protein, yet precisely how GA increases VHL expression remains to be elucidated. We previously reported that treatment of RCC cells with GA activates the Toxicity is an essential factor in clinical drug development. Our preliminary investigations confirmed that systemic administration of GA by either intravenous or intraperitoneal injection was lethal to mice. However, we found that repeated intratumoral injection of GA blocked tumor growth without causing significant toxicity. Intratumoral administration is by nature localized, and it improves the therapeutic index of drugs by increasing the tumor-to-organ ratio which greatly reduces systemic toxicity (50) . Although systemic administration is commonly regarded as essential for the treatment of invasive cancer, intratumoral injection is now a feasible approach for certain inoperable and/or metastatic tumor sites through the use of X-ray computed tomography. Furthermore, intratumoral administration can actually enhance immune responses against disseminated (non-injected) tumors by enhancing the processing of tumor-associated antigens expressed in cell debris from the injected tumor (51) . Nevertheless, systemic administration of GA may be possible in the near future.
Chemical modification of GA has been shown to change the characteristics of the peptide enough to increase microbial targeting and/or decrease non-specific toxicity (18, 19, 52, 53) , and encapsulation of GA within a targeted drug carriers such as nanoparticles may be a plausible method to safely deliver GA to only the tumor (54) . Whether these approaches can be 
